An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Additional locations may be listed on ClinicalTrials.gov for NCT00932893.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationPfizer Inc

• Primary IDA8081007
• Secondary IDsNCI-2010-00112, 2009-012595-27
• ClinicalTrials.gov IDNCT00932893